Search results for "aav"

Article Evaluating the Use of Continuous Chromatography
Continuous processes continue to advance in bioprocessing. In downstream processing, continuous chromatography is gaining traction in the purification of protein therapeutics. As the biopharma…

Article What is process development?
And ultracentrifugation to separate empty from full capsids of adeno-associated virus (AAV) does not scale well. Consider scalability from the start to avoid the need to rework your process. And…

Article From cells to purified capsids: How to develop a scalable rAAV process
In this webinar we present the latest updates to our work developing a scalable start-to-finish rAAV process. We produce and purify several serotypes, optimizing each step along the way. The key for a…

Article Recombinant Adeno-Associated Virus Type 5 Production Process
A scalable recombinant adeno-associated virus (rAAV) type 5 production process was developed using transfected HEK293 suspension cells. READ THE FULL ARTICLE >>

Article Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines
The most common viral vectors used in gene therapy are based on adeno-associated virus (AAV) and lentivirus. However, adenovirus and retrovirus are also of interest in this space (the latter being pri…

Article Technology Innovations Improve Process Chromatography Performance
As technology matures, inefficiencies and process limitations in downstream process chromatography are improved. By Feliza Mirasol Selecting an appropriate separation technology fo…

Article Production of Recombinant Adeno-associated Virus Vectors Using Microcarrier Culture of HEK293T Cells
As of March 2020, more than 4310 gene therapy clinical trials have been performed worldwide, with only 518 of them in Phase III and Phase IV. As the gene therapy projects enter clinical Phase III or g…

Article FDA Seeks to Enhance Manufacturing of Cell and Gene Therapies
He cited a lack of capacity for manufacture of lentiviral and adeno-associated virus (AAV) vectors for limiting clinical development and noted that the process of production in current cell lines is n…

Previous Page